TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10488555

Group type: EXPERIMENTAL
Intervention: Recognition hypermnesia with alternative retrieval pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different recognition procedure with three test trials
Number of subjects: 0
Study: 7574814

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy combined with hyperthermia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intra-arterial chemotherapy alone
Number of subjects: 26
Study: 2185964

Group type: EXPERIMENTAL
Intervention: Bacterial wall extract plus bacterial ribosomes (Immucytal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 387498

Group type: EXPERIMENTAL
Intervention: Oral trithiozine
Number of subjects: 1000
Study: 30835640

Group type: EXPERIMENTAL
Intervention: Video communication
Number of subjects: 40

Group type: COMPARATOR
Intervention: Telephone communication
Number of subjects: 40
Study: 30192007

Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26514065

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic group therapy (20 weekly sessions)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Long-term psychodynamic group therapy (80 weekly sessions)
Number of subjects: 167
Study: 26404954

Group type: EXPERIMENTAL
Intervention: Working memory training (experimental group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Active control (control group)
Number of subjects: 28
Study: 23706413

Group type: EXPERIMENTAL
Intervention: RYGB surgery (group C)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care plus Exenatide (group B)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (group A)
Number of subjects: 108
Study: 21369479

Group type: EXPERIMENTAL
Intervention: HA/CMC injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 19263035

Group type: EXPERIMENTAL
Intervention: Single-bundle reconstruction
Number of subjects: 26

Group type: COMPARATOR
Intervention: Double-bundle reconstruction
Number of subjects: 26
Study: 17244147

Group type: EXPERIMENTAL
Intervention: Cast post and core system (Ni-Cr)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fiber-reinforced resin posts (glass fiber: FRC Postec; quartz fiber: D.T. Light-Post)
Number of subjects: 30
Study: 15673186

Group type: EXPERIMENTAL
Intervention: Thinking aloud
Number of subjects: 58

Group type: COMPARATOR
Intervention: Silent condition
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Verbal protocols analysis
Number of subjects: 58
Study: 15475635

Group type: EXPERIMENTAL
Intervention: Low dose hepatitis B vaccine (2 mcg) given intradermally
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard dose hepatitis B vaccine (10 mcg) given intramuscularly
Number of subjects: 196
Study: 10030554

Group type: EXPERIMENTAL
Intervention: Carteolol hydrochloride 1.0%
Number of subjects: 112

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 112

Group type: COMPARATOR
Intervention: Comparison between Carteolol and Timolol
Number of subjects: 112
Study: 7577849

Group type: EXPERIMENTAL
Intervention: Gestrinone (2.5 mg twice weekly)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Danazol (200 mg twice daily)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 269
Study: 2022705

Group type: EXPERIMENTAL
Intervention: hCG (Profasi; 2000 IU, im)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 48
Study: 7049313

Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Haemorrhoidectomy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rubber band ligation and haemorrhoidectomy
Number of subjects: 80
Study: 28633702

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 2374

Group type: COMPARATOR
Intervention: Placebo (non-IPT)
Number of subjects: 2374

Group type: COMPARATOR
Intervention: MVA85A vaccine
Number of subjects: 2374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2374
Study: 26154184

Group type: EXPERIMENTAL
Intervention: Needle guidance technology (eZono)
Number of subjects: 100
Study: 23397969

Group type: EXPERIMENTAL
Intervention: Self-affirmation activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-affirmed Latino American students
Number of subjects: 0
Study: 20211501

Group type: EXPERIMENTAL
Intervention: Multidimensional exercise (twice a week for 3 months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 19584716

Group type: EXPERIMENTAL
Intervention: Pharmacist-driven alert system
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study: 17962426

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of 150 mg lamivudine, 300 mg zidovudine, and 200 mg nevirapine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Individual products (lamivudine, zidovudine, nevirapine)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fixed-dose combination and individual products
Number of subjects: 64
Study: 15078751

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 3408

Group type: COMPARATOR
Intervention: Questionnaire
Number of subjects: 3408
Study: 11211891

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b 3 MU tiw for 24 or 48 weeks plus ribavirin 1000‐1200 mg
Number of subjects: 912

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 912
Study: 9510317

Group type: EXPERIMENTAL
Intervention: 400 mg mesalazine suppositories administered three times per day
Number of subjects: 58

Group type: COMPARATOR
Intervention: 800 mg oral mesalazine tablets taken three times per day
Number of subjects: 58
Study: 7802191

Group type: EXPERIMENTAL
Intervention: Oscillometric finger cuffs
Number of subjects: 41
Study: 29587373

Group type: EXPERIMENTAL
Intervention: Deterministic algorithms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Randomized algorithms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fastest deterministic algorithm
Number of subjects: 6
Study: 26987935

Group type: EXPERIMENTAL
Intervention: Very low-dose factor VIII prophylaxis (10 units kg(‐1) body weight on 2 days a week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Episodic (On demand) factor concentrate in standard recommended doses
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Very low-dose factor VIII prophylaxis
Number of subjects: 21

Group type: COMPARATOR
Intervention: Episodic (On demand) factor concentrate
Number of subjects: 21
Study: 25343394

Group type: EXPERIMENTAL
Intervention: TCR (Total Caries Removal)
Number of subjects: 51

Group type: COMPARATOR
Intervention: PCR (Partial Caries Removal)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TCR
Number of subjects: 51

Group type: COMPARATOR
Intervention: PCR
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TCR and PCR
Number of subjects: 51
Study: 23636649

Group type: EXPERIMENTAL
Intervention: Casually intervened home‐based exercise group (CIHE)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intensely intervened home‐based exercise group (IIHE)
Number of subjects: 17
Study: 20658586

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 195
Study: 18971139

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 17161243

Group type: EXPERIMENTAL
Intervention: Clopidogrel + eptifibatide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 120
Study: 12938046

Group type: EXPERIMENTAL
Intervention: IRES-3 questionnaire
Number of subjects: 1818
Study: 10743876

Group type: EXPERIMENTAL
Intervention: Talk alone
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Talk to a validating confederate
Number of subjects: 256

Group type: COMPARATOR
Intervention: No-talk control condition
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Talk to an invalidating confederate
Number of subjects: 256
Study: 9361242

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 25
Study: 1488696

Group type: EXPERIMENTAL
Intervention: Rice-powder salt solution (RPSS) - 30 g/l rice powder and 3.5 g/l salt
Number of subjects: 64

Group type: COMPARATOR
Intervention: WHO recommended glucose electrolyte solution (WHO-ORS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Glycine supplemented WHO-ORS (G-ORS)
Number of subjects: 64
Study: 3566222

Group type: EXPERIMENTAL
Intervention: Lysozyme in combination with antibiotics
Number of subjects: 175

Group type: COMPARATOR
Intervention: Antibiotics without lysozyme
Number of subjects: 175
Study: 31399916

Group type: EXPERIMENTAL
Intervention: CAPA-IVM
Number of subjects: 40

Group type: COMPARATOR
Intervention: STD IVM
Number of subjects: 40
Study: 30203756

Group type: EXPERIMENTAL
Intervention: Valsartan combined with hydrochlorothiazide
Number of subjects: 160

Group type: COMPARATOR
Intervention: Valsartan (Control)
Number of subjects: 160
Study: 26833752

Group type: EXPERIMENTAL
Intervention: 1000 U/mL heparin (low dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5000 U/mL heparin (high dose)
Number of subjects: 100
Study: 24745013

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Modified transobturator tape (mTOT)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Mean surgery time for TVT
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Mean surgery time for TOT
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Mean surgery time for mTOT
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Mean hospitalization time
Number of subjects: 527

Group type: COMPARATOR
Intervention: Mean catheter maintenance time
Number of subjects: 527
Study: 22921260

Group type: EXPERIMENTAL
Intervention: Nabilone 1-4 mg/day (n=13)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 37
Study: 20805256

Group type: COMPARATOR
Intervention: Continuous antidepressant use in the placebo arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous antidepressant use in the lifestyle arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous antidepressant use in the metformin arm
Number of subjects: 0
Study: 19100930

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 1000
Study: 16197668

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg TID for 7 days (CYC5)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg TID plus Ibuprofen 400 mg TID (CYC5/IBU400)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg TID plus Ibuprofen 800 mg TID (CYC5/IBU800)
Number of subjects: 867

Group type: COMPARATOR
Intervention: All treatments (CYC5, CYC5/IBU400, CYC5/IBU800)
Number of subjects: 867
Study: 12114340

Group type: EXPERIMENTAL
Intervention: Respitin (60 mg/kg once weekly)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Prolastin (60 mg/kg once weekly)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Respitin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Respitin and Prolastin
Number of subjects: 26
Study: 10439755

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 40 mg orally with premedication, then 40 mg three times per day for 2 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo at identical times
Number of subjects: 50
Study: 8849208

Group type: EXPERIMENTAL
Intervention: Demiquet (male mass. demispan-2)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Mindex (female mass. demispan-1)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Demispan measurement
Number of subjects: 394
Study: 2189976

Group type: EXPERIMENTAL
Intervention: Infants with BPD
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 223
Study: 760920

Group type: EXPERIMENTAL
Intervention: isomers of flupenthixol
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study: 31944519

Group type: COMPARATOR
Intervention: 20% glycolic acid peel
Number of subjects: 90

Group type: COMPARATOR
Intervention: 15% lactic acid peel
Number of subjects: 90

Group type: COMPARATOR
Intervention: 12% ferulic acid peel
Number of subjects: 90
Study: 30571288

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (TR)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nonexercising control group (CON)
Number of subjects: 19
Study: 28245628

Group type: EXPERIMENTAL
Intervention: FOS (8 g/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 84
Study: 24720551

Group type: EXPERIMENTAL
Intervention: Mavrilimumab (10-100 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mavrilimumab (30 mg and 100 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mavrilimumab (100 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 24410973

Group type: EXPERIMENTAL
Intervention: Listening to Mozart K.448 daily before bedtime for at least six months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Listening to Mozart K.448
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 46
Study: 23016822

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 82
Study: 19220753

Group type: EXPERIMENTAL
Intervention: STW 5
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 18077808

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 16338555

Group type: EXPERIMENTAL
Intervention: Nasal hinge
Number of subjects: 47

Group type: COMPARATOR
Intervention: Superior hinge
Number of subjects: 47
Study: 12381742

Group type: EXPERIMENTAL
Intervention: L-tyrosine (25 mg/kg body wt)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polydextrose (70 g/l) and L-tyrosine (25 mg/kg body wt) (CHO+Tyr)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Polydextrose (70 g/l) (CHO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water sweetened with aspartame (placebo) (Pla)
Number of subjects: 9
Study: 9583332

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Control (nonstudy treatments)
Number of subjects: 1726
Study: 8674482

Group type: EXPERIMENTAL
Intervention: Wipe sampling
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Vacuum sampling
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Wipe samples correlation analysis
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 216
Study: 1975496

Group type: EXPERIMENTAL
Intervention: Mequitazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 362213

Group type: EXPERIMENTAL
Intervention: Insulin and glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regimen containing mainly fat (intralipid and sorbitol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (noncatabolic patients)
Number of subjects: 0
Study: 31886744

Group type: EXPERIMENTAL
Intervention: Angiotensin Converting Enzyme inhibitors (ACEis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAS molecules (Angiotensin II, Ang-(1-7))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAS targeting drugs (ACEis and ARBs)
Number of subjects: 0
Study: 30107536

Group type: EXPERIMENTAL
Intervention: α‐Cyclodextrin (α‐CD) 2 g per meal for 2 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: α‐Cyclodextrin (α‐CD)
Number of subjects: 8
Study: 26267851

Group type: EXPERIMENTAL
Intervention: TENS for 30 minutes and task oriented exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TENS for 60 minutes and task oriented exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Task oriented exercises
Number of subjects: 30
Study: 24106806

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) with propofol
Number of subjects: 220

Group type: COMPARATOR
Intervention: Intermittent bolus of cocktail regimen (midazolam, alfentanil, and propofol)
Number of subjects: 220
Study: 22728905

Group type: EXPERIMENTAL
Intervention: Sequential nephron blockade (group 1, n = 85)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Sequential renin-angiotensin system blockade (group 2, n = 82)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Sequential nephron blockade (group 1)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Sequential renin-angiotensin system blockade (group 2)
Number of subjects: 167
Study: 20625110

Group type: EXPERIMENTAL
Intervention: Remote home monitoring (HM)
Number of subjects: 1339

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 1339
Study: 18345713

Group type: EXPERIMENTAL
Intervention: FazaClo (clozapine orally disintegrating tablets) 100 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clozaril (clozapine standard oral tablets) 100 mg
Number of subjects: 36
Study: 16485521

Group type: EXPERIMENTAL
Intervention: Mild leg exercise (Ex)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Seated at rest (R)
Number of subjects: 8
Study: 12430146

Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT) using a KTP-dye module laser at 630 nm with a primary fluence rate of 100 mW cm(‐2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT)
Number of subjects: 15
Study: 11079734

Group type: EXPERIMENTAL
Intervention: Allergen-reduced dietary intervention (breastfeeding and moderate whey hydrolysate formula, pHF)
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Control group (infant formula with unhydrolysed proteins, IF)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Subanalysis of overall health findings in infants without a family risk of allergies
Number of subjects: 1130
Study: 8667280

Group type: EXPERIMENTAL
Intervention: Transmandibular implant (TMI)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IMZ implant system
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Brånemark system (BRA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: All implant systems (TMI, IMZ, BRA)
Number of subjects: 88
Study: 1866069

Group type: EXPERIMENTAL
Intervention: Cuprophane membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethylenevinylalcohol, polycarbonate, polymethylmethacrylate, acrylonitrile membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polysulphone and polyacrylonitrile membranes
Number of subjects: 0
Study: 6743781

Group type: EXPERIMENTAL
Intervention: Investigational oral formulation of flurazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available product of flurazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-1-desalkylflurazepam levels
Number of subjects: 0
Study: 30005843

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 15
Study: 29255960

Group type: EXPERIMENTAL
Intervention: Peer-mediated Pivotal Response Training (PRT)
Number of subjects: 11
Study: 27076184

Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DP)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Daily trimethoprim-sulfamethoxazole
Number of subjects: 469

Group type: COMPARATOR
Intervention: Monthly sulfadoxine-pyrimethamine
Number of subjects: 469

Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: HEU compared to HUU
Number of subjects: 469
Study: 26410876

Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EVBT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Balloon angioplasty (PTA)
Number of subjects: 44
Study: 23588438

Group type: EXPERIMENTAL
Intervention: Prebiotic mixture of 50% inulin and 50% fructo-oligosaccharide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (6 g of maltodextrin twice daily)
Number of subjects: 31
Study: 20424500

Group type: EXPERIMENTAL
Intervention: Training programme for general practitioners (The Extended Reattribution and Management model)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Control group (GPs not trained)
Number of subjects: 701
Study: 18551024

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control (current medication)
Number of subjects: 223
Study: 15843449

Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid treatment with 24 hour bed rest
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-articular glucocorticoid treatment with normal activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid treatment (both groups)
Number of subjects: 20
Study: 12392871

Group type: EXPERIMENTAL
Intervention: Computerized reminders recommending individualized changes in therapy
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Directed discussion by endocrinologists providing feedback on performance
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2000
Study: 10551706

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillators (ICDs)
Number of subjects: 1016
Study: 7738291

Group type: EXPERIMENTAL
Intervention: 0.5% carteolol
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.1% timolol
Number of subjects: 50